Affordable Access

Publisher Website

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Authors
Type
Published Article
Journal
The Lancet
1474-547X
Publisher
Elsevier
Publication Date
Volume
379
Issue
9834
Pages
2352–2363
Identifiers
DOI: 10.1016/S0140-6736(12)60768-5
PMID: 22632908
Source
Medline

Abstract

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments